021-51111890
购物车（）
sales@molnova.cn
BMS-754807
CAS No. 1001350-96-4
BMS-754807 ( BMS 754807;BMS754807 )
产品货号. M10014 CAS No. 1001350-96-4
BMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥518 | 有现货 |
|
| 5MG | ￥786 | 有现货 |
|
| 10MG | ￥1369 | 有现货 |
|
| 25MG | ￥2795 | 有现货 |
|
| 50MG | ￥4577 | 有现货 |
|
| 100MG | ￥6585 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称BMS-754807
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述BMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively.
-
产品描述BMS-754807 (BMS 754807, BMS754807)is a potent, reversible, orally active inhibitor of IGF-1R/Insulin receptor with IC50 of 1.8 and 1.7 nM, respectively; shows additional off-target activities Met, RON, TrkA, TrkB, AurA, and AurB (IC50=5-45 nM) in a panel of 27 kinases; inhibits the growth of a broad range of human tumor types in vitro (IC50=5-365 nM), induces PARP and Caspase 3 cleavage, promotes apoptosis; exhibits tumor growth inhibition in xenograft tumor models.Breast Cancer Phase 2 Discontinued
-
同义词BMS 754807;BMS754807
-
通路Angiogenesis
-
靶点IGF-1R
-
受体IGF-1R;InsulinReceptor;Met;TrkA;TrkB
-
研究领域Cancer
-
适应症Breast Cancer
化学信息
-
CAS Number1001350-96-4
-
分子量461.49
-
分子式C23H24FN9O
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESC[C@]1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F
-
化学全称2-Pyrrolidinecarboxamide, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-, (2S)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Wittman MD, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
2. Carboni JM, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
3. Dinchuk JE, et al. Endocrinology. 2010 Sep;151(9):4123-32.
4. Huang F, et al. Cancer Res. 2010 Sep 15;70(18):7221-31.
2. Carboni JM, et al. Mol Cancer Ther. 2009 Dec;8(12):3341-9.
3. Dinchuk JE, et al. Endocrinology. 2010 Sep;151(9):4123-32.
4. Huang F, et al. Cancer Res. 2010 Sep 15;70(18):7221-31.
产品手册
关联产品
-
Linsitinib
Linsitinib (ASP-7487, OSI-906) is a potent, selective, orally active, dual IGF-1R/insulin receptor inhibitor with IC50 of 35/75 nM, respectively.
-
Insulin(cattle)
Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells.
-
LMPTP INHIBITOR 1 hy...
LMPTP INHIBITOR 1 is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an IC50 of 0.8 μM LMPTP-A.
